Epigenetics Market Analysis and Reports | Switzerland Conference Series

Market Analysis - Epigenetics 2020

Epigenetics Technology Market covers the market by research and diagnostics areas in Gene Regulation studies, biomarker detection and drug discovery. It includes the factors driving and controlling the market and also covers the market scheme in the United State, Europe, Asia and all the other countries. Its market is determined to achieve USD 1,605.7 Million up to 2022. It is USD 854.0 Million in 2017, with CAGR of 13.5% amid anticipated period. The development of the market is dealt with by the diminishing sequencing costs, increment in explore exercises, rising Pervasiveness of Malignancy, and great government financing for epigenetics. Epigenetics has been picking up significance as a promising logical approach for understanding the impact of the epigenetic instruments in malignancy and different sicknesses. Fast progressions have been happening particularly in the field of Therapeutics.

Industry is seeing a more extensive acknowledgment as more number of academic research colleges; biotech and Pharma organizations will embrace Epigenetics based approach in Diagnostics and therapeutics.

 

On the basis of application, the market is bifurcated into Oncology and non-oncology. Oncology is further sub-segmented into solid tumors & liquid tumors and non-oncology is further categorized into inflammatory diseases, Metabolic Diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies & contract research organizations (CROs). Geographically, the market is analysed across Europe, North America, Asia-Pacific, and LAMEA.

Global Epigenetics Market was valued at $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023.

 

Figure: Epigenetics Market, by Geography, 2016-2023 

In view of geology, the business sector of Epigenetics is divided into North America, Europe, Asia, and the Rest of the World (RoW). North America is further subsegmented into U.S. also, Canada.

The real players in the worldwide epigenetics business sector are Illumina, Inc. (U.S.), Abcam plc. (U.K), QIAGEN N.V. (Netherland), Merck and Co. (U.S.), New England Biolabs, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Active Motif (U.S.), Diagenode, Inc. (Belgium) and Zymo Research Corporation (U.S.)

Global Epigenetics Market, by Product

  • Enzymes
  • Instruments and Consumables
  • Kits
  • Reagents
  • Bioinformatics Tools

Global Epigenetics Market, by Application

  • Oncology
  • Metabolic Diseases
  • Developmental Biology
  • Immunology
  • Cardiovascular Diseases
  • Other Applications

Global Epigenetics Market, by Technology

  • DNA Methylation
  • Histone Modifications
  • Other Technologies

Global Epigenetics Market, By End User

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)

Global Epigenetics Market, by Region

  • North America
    • US
    • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Rest of Asia Pacific
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Scope and Importance :

In biology, epigenetics is the study of heritable phenotype changes that do not involve alterations in the DNA Sequence. Epigenetics most often involves changes that affect gene activity and expression, but the term can also be used to describe any heritable phenotypic change. Such effects on cellular and physiological phenotypic traits may result from external or environmental factors, or be part of normal development. The standard definition of epigenetics requires these alterations to be heritable  in the progeny of either Cells or organisms.

The term also refers to the changes themselves: functionally relevant changes to the genome that do not involve a change in the nucleotide sequence. Examples of mechanisms that produce such changes are DNA Methylation and histone modification, each of which alters how genes are expressed without altering the underlying DNA sequence. Gene Expression can be controlled through the action of repressor proteins that attach to silencer regions of the DNA. These epigenetic changes may last through cell divisions for the duration of the cell's life, and may also last for multiple generations, even though they do not involve changes in the underlying DNA sequence of the organism; instead, non-genetic factors cause the organism's genes to behave (or "express themselves") differently.

One example of an epigenetic change in eukaryotic biology is the process of cellular differentiation. During morphogenesis, totipotent Stem cells become the various pluripotent cell lines of the embryo, which in turn become fully differentiated cells. In other words, as a single fertilized egg cell – the zygote – continues to divide, the resulting daughter cells change into all the different cell types in an organism, including neurons, muscle cells, epithelium, endothelium of blood vessels, etc., by activating some genes while inhibiting the expression of others.

Historically, some phenomena not necessarily heritable have also been described as epigenetic. For example, the term "epigenetic" has been used to describe any modification of chromosomal regions, especially histone modifications, whether or not these changes are heritable or associated with a phenotype. The consensus definition now requires a trait to be heritable for it to be considered epigenetic.

The principal objective of this conference is to provide an international platform for cutting edge research in Chromosome and Epigenetics.

The encompassing goal of this conference is to cover Chromatin and Chromosome Dynamics, Cytogenetics, Signaling to Chromosome, Nuclear Architecture and Dynamics, Developmental Epigenetics, Epigenomics, Epigenetics and Human Diseases, Genome Stability, Environmental Epigenetics, Tran’s Generational Inheritance, Functional Genomics, System Biology and Super Resolution Microscopy.

Our aim is to provide Cancer Surgeons, Oncologists, Young researchers, Students, Industrial Delegates and anyone professionally involved in study of Epigenetics, Oncology, Genetics and Radiology and Imaging with an opportunity to learn about the complexity of the disease, discuss interventional procedures, look at new and advanced epigenetic practices and their efficiency and efficacy in the treatment of various Diseases and Tumour Extraction, and understand local realities and practical constraints in improving health-care.